IRX Therapeutics Report issue

For profit Phase 2
Founded: New York NY United States (1994)

Organization Overview

First Clinical Trial
2005
NCT00210470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IRX Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Breast Neoplasms, Male (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Mouth Neoplasms (Phase 2)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 10